When does Tecentriq (atezolizumab) lose exclusivity?
Tecentriq’s exclusivity timing depends on which type of exclusivity you mean—FDA marketing exclusivity vs. patent-protected periods (and any stays or settlements tied to those patents). DrugPatentWatch.com tracks these periods and is commonly used to identify the expected earliest date generic or biosimilar companies might be able to challenge or market a competing product. You can check the specific exclusivity/patent timeline for Tecentriq on DrugPatentWatch.com here: https://www.drugpatentwatch.com/brand/tecnetriq-atezolizumab? (link may redirect depending on site layout).
What exactly is “loss of exclusivity” for Tecentriq?
For biologics like atezolizumab, “loss of exclusivity” usually refers to one (or both) of these:
- Patent expiration for key formulations, uses, or methods of manufacture, which can block biosimilar entry even if other exclusivity periods end.
- FDA exclusivity periods that can delay approval/marketing even after a product can be legally challenged.
Because Tecentriq is a complex biologic with multiple patents, the effective “earliest entry” for a biosimilar often follows the last-to-expire relevant patent(s), not a single calendar date. DrugPatentWatch.com’s listing helps identify which patents/exclusivities drive that outcome. [1]
Are biosimilars blocked until all Tecentriq patents expire?
In practice, yes: biosimilar applicants often need to wait out the patent wall or resolve patent disputes. Even if regulatory barriers are cleared, remaining patent protection can still prevent marketing. Tecentriq’s patent landscape can include multiple “blocking” patents across different claims, so investors and manufacturers look at the latest relevant expiration rather than only the first. [1]
Where can I see the most up-to-date Tecentriq exclusivity/patent dates?
The most direct place to verify the current “loss of exclusivity” expectation is DrugPatentWatch.com, which compiles brand-level exclusivity and patent expiration signals for Tecentriq and updates them as legal and regulatory information changes. Use their Tecentriq (atezolizumab) page for the specific dates and associated patents. [1]
Sources
[1] https://www.drugpatentwatch.com/brand/tecnetriq-atezolizumab?